1.
Effect of whole soy and purified daidzein on androgenic hormones in chinese equol-producing post-menopausal women: a six-month randomised, double-blinded and Placebo-Controlled trial.
Liu, ZM, Li, G, Zhang, D, Ho, SC, Chen, YM, Ma, J, Huang, Q, Li, S, Ling, WH
International journal of food sciences and nutrition. 2020;(5):644-652
Abstract
A randomised, double-blind and placebo-controlled trial was performed to examine the effects of whole soy and isoflavone daidzein on serum androgenic hormones in Chinese equol-producing post-menopausal women. A total of 270 eligible women aged 45-70 years were randomised to either one of the three iso-caloric supplements: 40 g soy flour (whole soy group), 40 g low-fat milk powder +63 mg daidzein (daidzein group) or 40 g low-fat milk powder (placebo group) daily for 6 months. Fasting venous samples were tested for serum androstenedione (AD), testosterone (T), prolactin, sex hormone binding globulin and dehydroepiandrosterone sulphate. Intention-to-treat analysis indicated that serum T (p = .022) and AD (p = .05) levels modestly but significantly decreased after 6-month daidzein treatment in comparison with placebo, with a mean difference of -0.057 nmol/L (95%CI: -0.185 to 0.070, p = .018) and -0.118 ng/mL (95%CI: -0.240-0.004, p = .045), respectively. This 6-month trial suggested that purified daidzein may exhibit less androgenic effect.Trial registration: The trial was registered in ClinicalTrials.gov with identifier of NCT01270737. (URL: http://clinicaltrials.gov/ct2/show/NCT01270737.).
2.
Effect of Pushen capsule for treating vascular mild cognitive impairment: a pilot observational study.
Li, S, Cao, G, Deng, Q, Zhu, D, Yan, F
The Journal of international medical research. 2019;(11):5483-5496
Abstract
OBJECTIVE Traditional Chinese medicine (TCM) may be beneficial for vascular dementia (VaD). We evaluated the efficacy of Pushen capsule, a compound containing several TCM components, for treating vascular mild cognitive impairment (VaMCI). METHODS Seventy outpatients with VaMCI were randomized to Pushen capsule or control treatment with Ginkgo biloba. Mini Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Subjective Memory Loss Rating Scale scores; and lipid, lipoprotein, and haemorheological parameters were collected at baseline, week 4, and week 12 of treatment. RESULTS MMSE score at week 12 was significantly higher in the treatment group compared with baseline (t = −2.352) but was not significantly different from week 12 in the control group. The MoCA score at week 12 was higher than that at baseline for both the treatment and control groups (t = −2.619 and −2.582, respectively), as was the “delayed recall” item score. Subjective memory loss score and the cognitive function “forgetting acquaintance's name” were significantly higher in the treatment group at week 12 than at baseline (t = −2.621 and χ2 = 4.419, respectively). Lipid, lipoprotein, and haemorheological parameters were significantly different after treatment in both groups. CONCLUSION The benefits of Pushen capsule on cognitive function in VaMCI were comparable with that of Ginkgo biloba.
3.
Patient characteristics associated with treatment response in patients receiving salvianolate injection for stable angina.
Qi, Y, Yu, C, Tang, L, Li, S, Sun, X
Journal of evidence-based medicine. 2018;(2):83-88
Abstract
OBJECTIVE To explore patient characteristics associated with treatment response in patients receiving salvianolate injection for stable angina. METHODS An analysis was conducted of data from a multicenter, phase IV clinical trial undertaken in China that enrolled 2150 patients hospitalized for stable angina from 50 hospitals. The treatment outcomes were changes of angina severity and nitroglycerin use between baseline and the last day of treatment. We used logistic regression models to explore patient characteristics associated with the treatment response. RESULTS Patients who were overweight or obese (ORa 1.20, 95% CI 1.01 to 1.44), present with hypertension (ORa 1.23, 95% CI 1.01 to 1.49), experienced with 3 or more episodes of angina per week (ORa 1.77, 95% CI 1.44 to 2.17), or concomitantly using antiplatelet agents (ORa 1.44, 95% CI 1.17 to 1.78) were associated with better treatment response defined with the change of angina severity. Those of overweight or obesity (ORa 1.57, 95% CI 1.17 to 2.12) or concomitantly using calcium antagonists (ORa 2.38, 95% CI 1.39 to 4.08) fared better treatment response according to discontinuation or reduction of nitroglycerin use. CONCLUSIONS Patients diagnosed with stable angina and receiving salvianolate injection might fare better treatment response if they were overweight or obese, experienced with hypertension, three or more episodes of angina per week, or concomitantly using antiplatelet agents and calcium antagonists.